Connect with us


‘It’s time to put medical cannabis back on the agenda’



Following the launch of Ireland’s first medical cannabis council earlier this month, campaigners are ready to put cannabis back on the agenda.

A new lobby group is bringing together some of Ireland’s most prominent campaigners to fight for long-awaitied access to medical cannabis.

Founded by leading advocates including Tom Curran, Gino Kenny, Vera Twomey and Alicia Maher, the Irish Medicinal Cannabis Council (IMCC), which launched in November, is focused on reducing stigma and improving education around cannabis in the medical profession and beyond.

The fight for access to medical cannabis has been ongoing for around a decade in Ireland, with campaigners describing a series of ‘false starts’ leaving the country lagging behind the rest of the world.

Around 40 patients – including Vera Twomey’s daughter 11-year-old Ava Barry, have been granted a Government license to import medical cannabis – but must travel overseas to access it.

In June 2019, the Medical Cannabis Access Programme was introduced, allowing consultants to prescribe to patients who have failed to respond to treatments for MS, intractable nausea and vomiting associated with chemotherapy and severe, refractory epilepsy.

However, so far no one has been prescribed cannabis through the scheme, with what is thought to be thousands of patients accessing it illicitly.

The first job of the IMCC will be to put cannabis back on the agenda among the nation’s leading politicians and legislators, Tom Curran told Cannabis Health.

“Medical cannabis hasn’t been on the agenda for years, so that will be our first priority, followed by showing the legislators how much it benefits people in other countries, as well as here,” said Tom, who became well-known for his advocacy after helping his late wife Marie Fleming access cannabis to treat her MS.

“There’s been 40 import licences given – if 40 people can benefit from it, there has to be hundreds or thousands of others that can benefit as well, so why is access denied to them?

“As a country there have been so many false starts, the idea of the group is to bring everybody together to finally get this over the line.”

As well as an education programme for medical professionals, the IMCC will be working to reduce the stigma associated with cannabis, which is still classed as a schedule one drug in Ireland, and often compared to heroin, cocaine and benzodiazepines.

“We’re one of the few countries in the world where cannabis is viewed as a more dangerous drug than heroin,” Tom continued.

“Politicians aren’t willing to tackle it because of the stigma – 10 years ago that would have been a valid point, because there was very little knowledge –  but since then the rest of the world has moved on.

“We failed to get over that hurdle. We didn’t provide the information that was necessary to change the politician’s minds and it became an issue that they just ignored.”

Earlier this year, the Irish Government did step in to facilitate the delivery of cannabis-based medicines for the 40 patients and their families who were suddenly unable to travel abroad due to the coronavirus pandemic.

However, the Health Services Executive (HSE) has recently confirmed that this arrangement will stop once restrictions are lifted.

While campaigners are calling for this to be extended, they ultimately want to see a system where patients can access their medicine in their home country.

“If our health department had acted in the way they said they would, there would be no need for the licencing system because the process would be in place for patients to access their medicine here in Ireland,” said Tom.

“We should be looking long-term, to make these licenses unnecessary and medical cannabis available to all patients who need it.”

He added: “We have hundreds, if not thousands of people using cannabis who are currently breaking the law. There’s no reason that any patient should have to break the law to get relief from the symptoms of whatever illness they have.”


Weekend digest: Six big stories from the cannabis world you might have missed



Another week, another rollercoaster in the fast-moving world of cannabis.

At Cannabis Health, our in depth coverage of the ongoing growth of cannabis as a medical and wellness product continues

Meanwhile, over at Cannabis Wealth, we’ve been following all the big industry and policy news in a week which has seen some important developments..

Been busy and want to get caught up in a hurry?

Here are the six things you need to read to stay in the loop this week.

1. Products pulled from shelves

Two batches of medical cannabis products have been recalled by regulators as investigations are carried out, following reports they may be contaminated with mould.

Medical cannabis pharmacy, Dispensary Green and the Medicines and Healthcare products Regulatory Agency (MHRA) have issued a ‘precautionary’ product recall since being made aware of ‘defects’ in patient’s medication.

Concerns were initially raised after a number of medical cannabis patients spotted what they believed to be mould spores in their prescriptions.

Full story here.

2. NFL turns to medical cannabis

The National Football League (NFL) in America is providing $1 million in funding for research into pain management and cannabinoids.

The NFL is funding research into medical cannabis.

The pain management committee of the NFL and the NFL Players Association announced it would stump up the funding on Tuesday 8 June.

According to the organisation’s news platform, the move is the next step in a shifting attitude towards players who use medicinal cannabis to manage pain from injuries.

You can read more here.

3. More medical cannabis evidence

Researchers have found that the cannabinoids CBD and CBG, when used in combination, are beneficial for treating inflammation in the lungs.

Scientists at King’s College London, working in collaboration with Sativa Wellness Group have published the first results from a study into the impact of cannabinoids on respiratory diseases.

It aimed to investigate the anti-inflammatory effects of the two non-psychotropic cannabinoids alone and in combination, in a model of pulmonary inflammation.

Full details here.

4. Germany to vote for reform?

Germany’s national election on September 26 could be a landmark moment for Europe’s cannabis industry.

As Chancellor Angela Merkel prepares to leave the stage, the European Union’s most influential country looks destined for a political shakeup.

Annalena Baerbock could become Germany’s first pro-drug reform Chancellor.

It could mark a huge moment for the cannabis industry as Germany’s parliament might swing in favour of legislation.

Here’s everything you need to know about it.

5. Adapt or fail

The pro-drug reform lobby must accept it has failed and change to push its agenda ahead, leading experts have warned.

Speaking at a Global Cannabis Intelligence event about the state of advocacy in the UK, three leading policy advocates set out how they think greater access can be achieved.

The discussion comes week after the 50-year anniversary of the passage of the The Misuse of Drugs Act.

Read the full story here.

6. Isle of Man steps up

The Isle of Man government has declared it is open for business to the medical cannabis industry.

In a big to create 250 new jobs and generate £3m a year for the island, policymakers want it to become ‘a world-leading exporter’.

Applications are now open for licences to produce and distribute treatments on the island, as well as to use it as an export base.

Full details here.

Continue Reading


New tracking app launches for UK medical cannabis patients

Through the app patients will be able to monitor their own symptoms and medication usage



The free health monitoring app is already being used elsewhere in the world.

UK medical cannabis suppliers Grow Pharma have teamed up with an Australian tech firm to launch a new app for patients.

The partnership with OnTracka will see them launch Calyx, a free health monitoring app already being used elsewhere in the world.

Users will be able to monitor their own symptoms and medication usage, speak securely with their doctor and contribute to gathering evidence about the use of medical cannabis.

The app will also be available in Ireland and the Channel Islands after successful launches in Australia, the US and South America.

Users will be able to monitor their own symptoms and medication usage

Pierre Van Weperen, CEO of Grow Pharma said: “Grow Pharma is currently fulfilling around a third of all prescriptions for the UK’s medicinal cannabis patients.

“Our prominent role gives us a significant advantage to building data insights into how patients are managing their health.

“This is integral to pave the way towards increasing access for patients in the UK through providing doctors with confidence around the safety and efficacy of these products.

“Using the app will generate important insights to provide real-time evidence to doctors and regulators.”

Grow Pharma hopes the app will help ‘rapidly accelerate an understanding of the safety, quality, and efficacy’ of medical cannabis.

Insights gained via the app will ‘advance the industry forward in the service of patients, shaping future legislation and policy based on patient experiences’ by providing real-world data to regulators.

Grow is in the process of raising £6 million worth of capital via a private funding round expect to be completed later this month.

Continue Reading


Isle of Man launches medical cannabis export sector

The Isle of Man is open for business to the medical cannabis industry.



The move could 250 new jobs and generate £3 million a year for the island

The Isle of Man government has declared it is open for business to the medical cannabis industry.

In a big to create 250 new jobs and generate £3 million a year for the island, policymakers want it to become ‘a world-leading exporter’.

Applications are now open for licences to produce and distribute treatments on the island, as well as to use it as an export base.

The island’s regulator – the Gambling Supervision Commission – has set out conditions for the licensing of high-THC cannabis and hemp.

Enterprise minister Laurence Skelly said: “The growing global medicinal cannabis market provides significant opportunity for economic development in the Isle of Man, and the new regulatory framework and guidance will offer stringent and flexible licensing of a broad range of cannabis products, which ranges from outdoor grown industrial hemp to indoor grown medicinal products.

“The Isle of Man Government has every confidence that the GSC will provide a world class regulatory structure required to regulate this new and complex industry.

The Isle of Man wants to be a major player in Europe’s growing medical cannabis industry.

“I am delighted to welcome licence applications and look forward to attracting quality businesses to the Island, transforming the cannabis export sector into a key contributor to the Isle of Man’s post-Covid economic recovery.”

The self-governing British Crown Dependency, which has a population of 83,000, approved new medical cannabis laws in January.

The island’s parliament – the Tynwald – moved to attract the industry to its shores after a public consultation showed 95 percent of residents were in favour of the policy.

Mark Rutherford, director of policy at the island’s regulator, said: “The GSC already has a sophisticated framework for supervising gambling.

‘We have worked carefully to apply the best of that framework to the risks in the new sector and we have educated ourselves in the technical areas that are new to us.

“What we now have will ensure that all stakeholders will be competent, crime free and capable of building a sector that is safe, trusted and efficient.

“As regulators, we aspire to put our regulatory umbrella above as many consumers as possible so that they can benefit from regulations that are well thought out and properly supervised.

“Years of prohibition mean that the markets in which our licensees will be participating are still in their infancy and still contain many uncertainties.

“To address this situation, it is our aim to ensure that consumers who purchase Isle of Man products will be able to understand exactly what their product contains through accurate labelling and independent testing.

“The GSC recognises there are many stakeholders in this newly created field and intends to extend its ethos of cooperation with other government authorities into its approach to cannabis regulation.”

Continue Reading